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those obtained by DPS or GC-MS levels, suggesting that a fraction 
of Bu binds to blood cells.
Conclusion: This novel method can be applied with only 5 μ L of 
whole blood for routine therapeutic drug monitoring of Bu with 
accuracy and faster turnaround times in HSCT. Possibility of using 
capillary blood for dried blood sampling is under evaluation for its 
feasibility and accuracy to monitor Bu levels in pediatric patients.
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Introduction: Imatinib trough plasma concentrations (Cmin) have 
been correlated with treatment response in chronic myeloid leukemia 
(CML) patients. The use of Cmin monitoring for optimizing imatinib 
dosage (therapeutic drug monitoring [TDM]) is therefore proposed 
for patients with unsatisfying response or tolerance (“rescue TDM”). 
A cycle of “routine TDM” for dosage individualization could also 
be beneficial to prevent unfavorable events, yet its clinical usefulness 
has not been evaluated. We aimed to assess prospectively whether 
a “routine TDM” intervention targeting imatinib Cmin of 1000 ng/mL 
(tolerance, 750–1500 ng/mL) could improve efficacy, tolerance, and 
persistence on treatment compared with “rescue TDM” use only.
Patients (or Materials) and Methods: The Swiss Imatinib 
COncentration Monitoring Evaluation (I-COME) study was a multi-
center randomized controlled trial (ISRCTN31181395). Adult patients 
in chronic or accelerated phase CML receiving imatinib ≤5 years were 
eligible. Patients were randomly (1:1) allocated to receive “routine 
TDM” intervention or to serve as controls with access only to “res-
cue TDM”. All had 1-year follow-up. The primary endpoint was a 
combined efficacy-safety outcome (failure- and toxicity-free survival 
without imatinib discontinuation), analyzed in intention-to-treat.
Results: Among 56 CML recruited patients, 55 had their molecular 
and cytogenetic response measured. 14/27 of patients receiving “rou-
tine TDM” (52% [33%–71%]) remained event-free versus 16/28 of 
control patients with “rescue TDM” only (57% [39%–75%]; P = 
0.69). In the “routine TDM” group, dosage recommendations were 
adopted entirely in 50% of patients (median Cmin at study end, 895 
ng/mL; CV = 33%). These patients had fewer unfavorable events 
(28% [5%–52%]) compared with patients not receiving the advised 
dosage (77% [54%–99%]; P = 0.03; median Cmin at study end, 648 
ng/mL; CV = 38%).
Conclusion: This first prospective target concentration intervention 
trial could not formally demonstrate a benefit of “routine TDM” 
of imatinib, especially due to a small patient number and limited 
prescriber’s adherence to dosage recommendations. Nevertheless, 
the patients receiving the advised dosage more often met target 
concentrations and the combined outcome (efficacy, tolerance, and 
persistence). A cycle of routine TDM could thus be favorable, at 
least in patients eligible for dosage adjustment. Its usefulness should, 
however, be further confirmed in larger trials.
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Introduction: Ponesimod is a selective sphingosine-1 phosphate 
(S1P1) receptor modulator currently in clinical development for 
multiple sclerosis and plaque psoriasis. The aim of this study was 
to assess the maximum tolerated dose of increasing multiple doses 
(3-day titration steps) of ponesimod in healthy subjects.
Patients (or Materials) and Methods: This was a single-center, dou-
ble-blind, placebo-controlled, randomized, parallel-group, up-titra-
tion study in healthy male and female subjects (n = 16). The subjects 
received ascending oral doses either of ponesimod (n = 12) or placebo 
(n = 4) once daily for 3 days at each dose level (10 mg, 20 mg, 40 
mg, 60 mg, 80 mg, 100 mg). The pharmacodynamics of ponesimod 
were assessed by measuring the total lymphocyte count. The safety 
and tolerability was evaluated by monitoring adverse events, assess-
ing standard blood chemistry and hematology laboratory variables, 
12-lead ECG recordings and telemetry, measuring of vital signs, and 
pulmonary function tests (PFTs).
Results: A plateau in mean lymphocyte count reduction from base-
line of ~70% was reached at the 40-mg dose level. The most frequent 
adverse events, all of mild to moderate intensity, were chest discom-
fort (experienced by 58% of subjects), headache (50%), dizziness 
(42%), dyspnea (42%), abdominal pain (33%), and night sweats 
(25%). A transient decrease in heart rate was observed after adminis-
tration of the first 10-mg ponesimod dose (–9 bearts/min at 1.5 hours 
postdose [placebo, –2 beats/min]). After up-titration from 10 to 20 
mg (–7 beats/min at 1.5 hours postdose [placebo, –5 beats/min]) and 
following up-titration to higher doses, the decrease in heart rate with 
ponesimod was similar to placebo, suggesting that desensitization to 
the heart rate effect had occurred. A dose-dependent decrease in PFTs 
was observed and reached a plateau with 60-mg ponesimod (maximal 
mean decrease of 1.24 L [–30.5%] in forced expiratory volume in 1 
second [FEV1] and 0.70 L [–13.7%] in forced vital capacity [FVC]). 
At the dose levels of 80 to 100 mg, several subjects reported chest 
discomfort and dyspnea. The effects on heart rate, lymphocytes, and 
PFTs were fully reversible and reached baseline values within 10 days 
after discontinuation of treatment.
Conclusion: Ponesimod was tolerated by subjects exposed to doses 
of 10 to 100 mg during the 18-day up-titration regimen. The maxi-
